Skip to main content

Urologic Diseases

2
Pipeline Programs
8
Companies
9
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
2
Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mgPhase 11 trial
Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mgPhase 11 trial
Active Trials
NCT02058576Completed77Est. Jan 2015
NCT02052713Completed78Est. Dec 2014
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
2 programs
CEGSSS-Canadian Endourology Group Stent Symptom ScoreN/A1 trial
Oculus Go VRN/A1 trial
Active Trials
NCT04909541Recruiting180Est. Sep 2025
NCT04251988Unknown410Est. Dec 2023
Bright Uro
Bright UroCA - Irvine
2 programs
Glean Urodynamics SystemN/A1 trial
Glean Urodynamics SystemN/A1 trial
Active Trials
NCT05694793Recruiting28Est. Jul 2026
NCT05959655Completed38Est. Apr 2024
MSD
MSDIreland - Ballydine
1 program
Audit-and-feedbackN/A
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Audit-and-feedbackN/A1 trial
Active Trials
NCT04196777Completed525Est. Aug 2023
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
Audit-and-feedbackN/A
Coloplast
ColoplastAustralia - Mulgrave
1 program
Coloplast TFL DriveN/A1 trial
Active Trials
NCT06257368Unknown373Est. Dec 2025
Young BioPharma
Young BioPharmaMA - Lowell
1 program
Prosocial-orientated Acceptance and Commitment Training plus positive parenting adviceN/A1 trial
Active Trials
NCT05467527Recruiting196Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ViiV HealthcareCommercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg
ViiV HealthcareCommercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg
Bright UroGlean Urodynamics System
Bright UroGlean Urodynamics System
ColoplastColoplast TFL Drive
Merck & Co.Audit-and-feedback
Young BioPharmaProsocial-orientated Acceptance and Commitment Training plus positive parenting advice
Angeles TherapeuticsCEGSSS-Canadian Endourology Group Stent Symptom Score
Angeles TherapeuticsOculus Go VR

Clinical Trials (9)

Total enrollment: 1,905 patients across 9 trials

NCT02052713ViiV HealthcareCommercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg

Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State

Start: Feb 2014Est. completion: Dec 201478 patients
Phase 1Completed
NCT02058576ViiV HealthcareCommercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg

Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State

Start: Feb 2014Est. completion: Jan 201577 patients
Phase 1Completed
NCT05694793Bright UroGlean Urodynamics System

Trial for Reliability of Urodynamics SysTem

Start: Jun 2025Est. completion: Jul 202628 patients
N/ARecruiting
NCT05959655Bright UroGlean Urodynamics System

Modern Urodynamics System Efficacy (MUSE) Study

Start: Aug 2023Est. completion: Apr 202438 patients
N/ACompleted
NCT06257368ColoplastColoplast TFL Drive

TFL Driven Urinary System Treatment Study

Start: Jul 2023Est. completion: Dec 2025373 patients
N/AUnknown
NCT04196777Merck & Co.Audit-and-feedback

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

Start: Aug 2022Est. completion: Aug 2023525 patients
N/ACompleted
NCT05467527Young BioPharmaProsocial-orientated Acceptance and Commitment Training plus positive parenting advice

PACT Programme for Parents of Children With SHCN

Start: Jun 2022Est. completion: Dec 2025196 patients
N/ARecruiting
NCT04909541Angeles TherapeuticsCEGSSS-Canadian Endourology Group Stent Symptom Score

Development of a New Canadian Endourology Group Stent Symptom Score

Start: May 2022Est. completion: Sep 2025180 patients
N/ARecruiting
NCT04251988Angeles TherapeuticsOculus Go VR

VR to Reduce Pain and Anxiety During GU Scans

Start: Feb 2020Est. completion: Dec 2023410 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 1,905 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.